Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor INCB24360 in combination with Genentech’s PD-L1
combination הגייה עם משמעויות, מילים נרדפות, הפכים, תרגומים, משפטים ועוד